• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

艾曲泊帕治疗免疫性血小板减少症并发的2支冠状动脉同时发生亚急性支架内血栓形成

Simultaneous Subacute Stent Thrombosis of 2 Coronary Arteries Complicating Immune Thrombocytopenia Treated by Eltrombopag.

作者信息

Sato Shingo, Katsura Aritomo, Ando Jiro, Warisawa Takayuki

机构信息

Department of Cardiology, NTT Medical Center Tokyo, Tokyo, Japan.

Department of Cardiology, NTT Medical Center Tokyo, Tokyo, Japan.

出版信息

JACC Case Rep. 2025 Mar 19;30(6 Pt 1):102941. doi: 10.1016/j.jaccas.2024.102941. Epub 2025 Jan 8.

DOI:10.1016/j.jaccas.2024.102941
PMID:40118604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12011142/
Abstract

Simultaneous subacute occlusion of the latest drug-eluting stents in 2 coronary arteries was documented in an immune thrombocytopenia patient receiving eltrombopag while undergoing potent dual antiplatelet therapy. Careful consideration is needed for the interruption of eltrombopag and the timing of staged percutaneous coronary intervention after the initial coronary event.

摘要

在一名接受艾曲泊帕治疗且正在接受强效双联抗血小板治疗的免疫性血小板减少症患者中，记录到同时发生2条冠状动脉内最新药物洗脱支架的亚急性闭塞。对于艾曲泊帕的中断以及初始冠状动脉事件后分期经皮冠状动脉介入治疗的时机，需要仔细考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/8a15c4b9a994/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/9ac469550585/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/5ad7db517731/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/8a15c4b9a994/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/9ac469550585/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/5ad7db517731/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0d/12011142/8a15c4b9a994/gr2.jpg

相似文献

1
Simultaneous Subacute Stent Thrombosis of 2 Coronary Arteries Complicating Immune Thrombocytopenia Treated by Eltrombopag.艾曲泊帕治疗免疫性血小板减少症并发的2支冠状动脉同时发生亚急性支架内血栓形成
JACC Case Rep. 2025 Mar 19;30(6 Pt 1):102941. doi: 10.1016/j.jaccas.2024.102941. Epub 2025 Jan 8.
2
Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag.一名慢性免疫性血小板减少症患者出现复发性冠状动脉血栓并接受艾曲泊帕治疗
Case Rep Cardiol. 2019 Mar 26;2019:2756319. doi: 10.1155/2019/2756319. eCollection 2019.
3
Perioperative management of antiplatelet therapy in patients with drug-eluting stents.药物洗脱支架植入患者围手术期抗血小板治疗的管理
HSR Proc Intensive Care Cardiovasc Anesth. 2012;4(3):153-67.
4
Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).晚期和极晚期药物洗脱支架血栓形成的相关因素和结果：DESERT（国际药物洗脱支架血栓形成事件注册研究）的结果。
JACC Cardiovasc Interv. 2014 Oct;7(10):1093-102. doi: 10.1016/j.jcin.2014.04.017. Epub 2014 Sep 17.
5
Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.双联抗血小板治疗患者的药物洗脱支架或裸金属支架内血栓形成。
JACC Cardiovasc Interv. 2015 Oct;8(12):1552-62. doi: 10.1016/j.jcin.2015.05.026.
6
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.双重抗血小板治疗研究的原理和设计，一项前瞻性、多中心、随机、双盲试验，旨在评估接受药物洗脱支架或裸金属支架置入治疗冠状动脉病变的经皮冠状动脉介入治疗患者接受 12 个月与 30 个月双重抗血小板治疗的有效性和安全性。
Am Heart J. 2010 Dec;160(6):1035-41, 1041.e1. doi: 10.1016/j.ahj.2010.07.038.
7
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.载有佐他莫司的药物洗脱支架置入后双联抗血小板治疗 3 个月与 12 个月：OPTIMIZE 随机试验。
JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183.
8
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.急性心肌梗死后经皮冠状动脉介入治疗后支架血栓形成的频率及预测因素。
Circulation. 2011 Apr 26;123(16):1745-56. doi: 10.1161/CIRCULATIONAHA.110.981688. Epub 2011 Apr 11.
9
Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention.左主干分叉经皮冠状动脉介入治疗中 2 支架策略而非 1 支架策略后双联抗血小板治疗时间决定结局。
JACC Cardiovasc Interv. 2018 Dec 24;11(24):2453-2463. doi: 10.1016/j.jcin.2018.09.020.
10
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism.由CYP2C19基因多态性导致的氯吡格雷抵抗引起的同时性双支血管亚急性支架内血栓形成
Case Rep Med. 2016;2016:2312078. doi: 10.1155/2016/2312078. Epub 2016 Jul 31.

本文引用的文献

1
Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis.血小板生成药物治疗免疫性血小板减少症患者时血栓形成事件的风险：一项系统评价和荟萃分析。
Thromb J. 2023 Jun 23;21(1):69. doi: 10.1186/s12959-023-00509-z.
2
Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.急性冠状动脉综合征合并多支冠状动脉疾病患者的即刻与分期完全血运重建（BIOVASC）：一项前瞻性、开放标签、非劣效性随机试验。
Lancet. 2023 Apr 8;401(10383):1172-1182. doi: 10.1016/S0140-6736(23)00351-3. Epub 2023 Mar 5.
3
Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
艾曲泊帕治疗前后慢性免疫性血小板减少症促凝状态的评估——一项前瞻性队列研究
J Thromb Haemost. 2023 Apr;21(4):1020-1031. doi: 10.1016/j.jtha.2022.11.039. Epub 2022 Dec 22.
4
Refractory Coronary Stent Thrombosis in a Patient with Chronic Immune Thrombocytopenia on Eltrombopag.接受艾曲泊帕治疗的慢性免疫性血小板减少症患者发生难治性冠状动脉支架内血栓形成
Acta Cardiol Sin. 2021 Sep;37(5):542-545. doi: 10.6515/ACS.202109_37(5).20210518A.
5
Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag.一名慢性免疫性血小板减少症患者出现复发性冠状动脉血栓并接受艾曲泊帕治疗
Case Rep Cardiol. 2019 Mar 26;2019:2756319. doi: 10.1155/2019/2756319. eCollection 2019.
6
Procoagulant profile in patients with immune thrombocytopenia.免疫性血小板减少症患者的促凝血特征
Br J Haematol. 2016 Dec;175(5):925-934. doi: 10.1111/bjh.14412. Epub 2016 Oct 21.
7
Prasugrel versus clopidogrel in patients with acute coronary syndromes.普拉格雷与氯吡格雷用于急性冠状动脉综合征患者的比较。
N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4.